Funded by the Medical Research Council part of UK Research and Innovation, the LEGACY03 trial will contribute to future vaccine designs to enhance protection for those most vulnerable to diseases.
As the immune systems changes with age, the body’s response to vaccines evolves. Additionally, the risk of complications from infections increases, and therefore, better-tailored vaccines are essential to achieve maximum efficacy and protect the most vulnerable.
